SYRS — Syros Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$17.19m
- $9.94m
Brief: Syros Presents Data From Phase 1/1B Clinical Trial Of Sy-5609 In Advanced Solid Tumors At ASCO Annual Meeting
Syros Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Syros Reports Q1 2023 Financial Results And Provides A Corporate Update
Syros Pharmaceuticals Inc expected to post a loss of $1.09 a share - Earnings Preview
Brief: Syros Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 Million – SEC Filing
Brief: Syros Pharmaceuticals Inc - Discloses That, As Of March 10, 2023, It Has Two Deposit Accounts At Silicon Valley Bank
Syros Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Syros Reports Fourth Quarter And Full Year 2022 Financial Results And Provides A Corporate Update
Syros Pharmaceuticals Inc expected to post a loss of $1.35 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Xerox, AC Immune, OpGen
Syros Pharma rises on 'fast-track' tag for blood disorder drug
Brief: Syros Receives Fast Track Designation From FDA For Tamibarotene
Brief: Syros Pharmaceuticals Inc Expects To Complete Enrollment In Select-Mds-1 Late-stage Study In 4Q 2023
Brief: Syros Presents Safety Lead-In Data From Select-Aml-1 Trial Evaluating Tamibarotene In Combination With Venetoclax And Azacitidine And Announces Plans To Initiate Randomized Portion Of Phase 2 Trial
Syros Pharma gains on positive cancer therapy trial data
Syros Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Syros Pharmaceuticals Inc Q3 Loss Per Share $3.21
Syros Pharmaceuticals Inc expected to post a loss of $4.01 a share - Earnings Preview
Brief: Syros Pharmaceuticals To Present Initial Data From Select-Aml-1 Phase 2 Trial At 64Th Ash Annual Meeting